Health News

Intellect Neurosciences, Inc announced that it has received a Notice of Allowance from the Canadian Patent and Trademark Office for a new patent related to OX1 (OXIGON™), the Company’s clinical-stage drug candidate that has disease-modifying potential for Alzheimer’s and other neurodegenerative disorders. OX1 is an orally-administered, brain-penetrating, naturally-occurring, copper-binding small molecule targeting multiple mechanisms that contribute significantly to the underlying pathology of Alzheimer’s disease.

Read more

Filed under: Pharmacy News
Tags: brain, Drug, Pharmacy

Related posts

• Zileuton can help reduce amyloid plaque formation and Alzheimer’s development (0)
  A drug used to treat asthma has been shown to help reduce the formation of amyloid beta, a peptide in the brain that is implicated in the development of Alzheimer's disease, according to researchers at Temple University's School of Medicine. Read more [tags] Pharmacy News [/tags]
  
  
• Valproic acid may increase survival for brain tumor patients (0)
  New research suggests brain tumor patients who take the seizure drug valproic acid on top of standard treatment may live longer than people who take other kinds of epilepsy medications to control seizures. Read more [tags] Pharmacy News [/tags]
  
  
• Vaccine To Treat Nicotine Addiction Steps Closer To Market As Companies Agree Option Deal (0)
  An experimental vaccine called NicVAX, designed to treat nicotine addiction that works by stopping the drug from reaching the brain, moved a step closer to the market when the vaccine developer Nabi Biopharmaceuticals (Nabi), based in Rockville, Maryland, US agreed an option and licensing deal with GlaxoSmithKline [...]
  
  
• USPTO grants second patent to Angiochem’s EPiC drugs (0)
  Angiochem, Inc., a clinical stage biotechnology company, today announced that its second patent has been granted by the U.S. Patent and Trademark office. Patent number 7,902,156, is entitled "Aprotinin Polypeptides for Transporting a Compound Across the Blood-Brain Barrier". Read more [tags] Pharmacy News [/tags]
  
  
• Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI (0)
  Transition Therapeutics Inc. announced today that the first patient has been dosed with drug candidate TT-301 in a Phase 1 clinical study. TT-301 is a small molecule compound that has demonstrated efficacy in preclinical models of rheumatoid arthritis, intracerebral haemorrhage and traumatic brain injury. Read more [tags] Pharmacy News [/tags]